1. Scrip
  2. >>Business

Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J

 
• By Joseph Haas

J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.

Arrowheads
Arrowhead will take over NASH candidate once licensed to J&J • Source: Shutterstock

Possibly putting the best face forward on a deep-pocketed partner leaving a collaboration, Arrowhead Pharmaceuticals, Inc. CEO Christopher Anzalone told Scrip his company is excited to reacquire non-alcoholic steatohepatitis (NASH) candidate ARO-PNPLA3/JNJ-75220795 from Johnson & Johnson, saying on 15 February the Phase I candidate could offer a clear shot on goal in a well-defined NASH subpopulation.

J&J is undertaking a strategic review of its pipeline and notified Arrowhead within the past few days that it will return the NASH candidate it optioned under a multi-target liver disease alliance the two firms signed in October 2018. (Also see "J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B" - Scrip, 4 October, 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.